TY - JOUR
T1 - Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents
T2 - US Preventive Services Task Force Recommendation Statement
AU - US Preventive Services Task Force
AU - Mangione, Carol M.
AU - Barry, Michael J.
AU - Nicholson, Wanda K.
AU - Cabana, Michael
AU - Chelmow, David
AU - Coker, Tumaini Rucker
AU - Davidson, Karina W.
AU - Davis, Esa M.
AU - Donahue, Katrina E.
AU - Jaén, Carlos Roberto
AU - Kubik, Martha
AU - Li, Li
AU - Ogedegbe, Gbenga
AU - Pbert, Lori
AU - Ruiz, John M.
AU - Stevermer, James
AU - Tseng, Chien Wen
AU - Wong, John B.
PY - 2022/9/13
Y1 - 2022/9/13
N2 - Importance: The Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents. Objective: The US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation. Population: Children and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes. Evidence Assessment: The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. (I statement).
AB - Importance: The Centers for Disease Control and Prevention estimates that 210 000 children and adolescents younger than 20 years had diabetes as of 2018; of these, approximately 23 000 had type 2 diabetes. Youth with type 2 diabetes have an increased prevalence of associated chronic comorbid conditions, including hypertension, dyslipidemia, and nonalcoholic fatty liver disease. Data indicate that the incidence of type 2 diabetes is rising; from 2002-2003 to 2014-2015, incidence increased from 9.0 cases per 100 000 children and adolescents to 13.8 cases per 100 000 children and adolescents. Objective: The US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant persons younger than 18 years. This is a new recommendation. Population: Children and adolescents younger than 18 years without known diabetes or prediabetes or symptoms of diabetes or prediabetes. Evidence Assessment: The USPSTF concludes that the evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. There is a lack of evidence on the effect of screening for, and early detection and treatment of, type 2 diabetes on health outcomes in youth, and the balance of benefits and harms cannot be determined. Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for type 2 diabetes in children and adolescents. (I statement).
UR - http://www.scopus.com/inward/record.url?scp=85138445570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138445570&partnerID=8YFLogxK
U2 - 10.1001/jama.2022.14543
DO - 10.1001/jama.2022.14543
M3 - Review article
C2 - 36098719
AN - SCOPUS:85138445570
SN - 0002-9955
VL - 328
SP - 963
EP - 967
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 10
ER -